American Heart Association announces late-breaking research for Scientific Sessions 2024
The American Heart Association's Scientific Sessions 2024 conference in Chicago will include numerous late-breaking studies and featured science presentations. These studies represent some of the most highly anticipated findings that will be shared during the three-day event.
More information on these and other AHA sessions can be found here.
Celebrating a Century of Cardiovascular Science: From Prevention to Treatment, to Cure
Saturday, Nov. 16, 8:30 - 9:45 a.m. (Central), Main Event I
• A century of cardiovascular disease prevention- health challenges in the two extremes of life
• Effects of Intensive Blood Pressure Control in Patients with Type 2 Diabetes: BPROAD study. Presented by Guang Ning.
• Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial. Presented by Milton Packer.
• Nexiguran ziclumeran (nex-z, also known as NTLA-2001), an investigational in vivo CRISPR-based therapy for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM): interim report of the Phase 1 study. Presented by Marianna Fontana.
Featured Science: Novel Approaches to Managing Lipid Risk
Saturday, Nov. 16, 1:30 - 2:45 pm, S100A
• Novel Lipid Targets and Vascular Outcomes. Presented by Peter Libby.
• Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial
Presented by Dean J. Kereiakes.
• Efficacy and Safety of Lerodalcibep, a Third Generation PCSK9 Inhibitor in 703 Heterozygous Familial Hypercholesterolemia Subjects in the Open Label Extension Trial: LIBerate-OLE, LIBerate-HeFH-OLE. Presented by Frederick Johan Raal.
• PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP). Presented by Gerald F. Watts.
• Transcriptomic Signatures and Predictors of Evolocumab Added to Maximum Statin Therapy Based on Intra-Coronary Plaque Characteristics: YELLOW III Study. Presented by Annapoorna Subhash Kini.
Featured Science: Health Technology and the Future of Clinical Trials
Saturday, Nov. 16, 1:30 - 2:45 p.m., S104B
• Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials. Presented by Jonathan Cunningham.
• Manual versus AI-Assisted Clinical Trial Screening using Large-Language Models (MAPS-LLM). Presented by Ozan Unlu.
• Personalized App-Based Coaching Improves Physical Activity in Patients With HFpEF Compared to Standard Care – A Randomized Parallel Group Trial (MyoMobile Study). Presented by Silav Zeid.
• Impact of Technology-Enabled Home-Based Cardiac Rehabilitation on Functional Status and Cardiovascular Health Metrics: The American Heart Association Health Technology Network mTECH-Rehab Randomized Controlled Trial. Presented by Chang Kim.
Redefining Arrhythmia Treatment: Pushing Boundaries
Saturday, Nov. 16, 1:30 - 2:45 p.m., Main Event I
• Evolution of Care of Patients with Arrhythmia. Presented by Eric N. Prystowsky.
• Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia in Ischemic Cardiomyopathy: VANISH2 trial. Presented by John L. Sapp.
• Randomized Comparison of Left Atrial Appendage Closure with Oral Anticoagulation after Catheter Ablation for Atrial Fibrillation: OPTION. Oussama Musbah Wazni
• Blinded Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation: BRAIN AF. Presented by Lena Rivard.
Smart Cardiology: Harnessing AI and Innovation for Better Heart Health
Saturday, Nov. 16, Main Event I, 3:15 - 4:30 p.m.
• Evaluation of Randomized Audit and Feedback to Increase Heart Failure Medication Optimization Among Primary Care Pharmacists in the Veterans Affairs Health Care System (PHARM-HF A&F Study). Presented by Alexander T. Sandhu.
• Novel AI to Assess Intracardiac Filling Pressure: The Non-invasive SEISMocardiogram In Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF I) Study. Presented by Liviu Klein.
• Artificial Intelligence-based Automated ECHOcardiographic Measurements and the Workflow of Sonographers (AI-ECHO): Randomized Crossover Trial. Presented by Nobuyuki Kagiyama.
• PanEcho: Complete AI-enabled echocardiography interpretation with multi-task deep learning. Presented by Gregory Holste, Rohan Khera.
Featured Science: Getting Closer to the Summit: New HFpEF Treatments
Sunday, Nov. 17, 8 - 9:15 a.m., S100A
• The Arc of Heart Failure. Presented by Marc A Pfeffer.
• Effect of finerenone on a hierarchical composite endpoint analyzed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF. Presented by Toru Kondo.
• Efficacy and safety of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified sex-specific analysis of the FINEARTS-HF trial. Presented by Misato Chimura.
• Finerenone and Risk of Hyperkalemia in Patients With Heart Failure with Mildly Reduced or Preserved Ejection Fraction. Presented by Orly Vardeny.
• Effects of Tirzepatide on Cardiorenal End-Organ Damage in Heart Failure and Preserved Ejection Fraction: Insights from the SUMMIT trial. Presented by Barry A. Borlaug.
• Bisecting the Future of HFpEF Therapy: Medical and Procedural Therapy. Presented by Nosheen Reza.
From Intervention to Prevention: Advances in Coronary and Valvular Heart Disease
Sunday, Nov. 17, 8 - 9:15 a.m., Main Event I
• From STICH to GLORIOUS: The evolution of coronary interventions.
• Efficacy of Restrictive versus Liberal Oxygenation in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement – a randomized clinical trial. Presented by Sebastian Wiberg.
• Efficacy of a Glucagon-Like Peptide-1 Agonist in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement – a randomized clinical trial: GLORIOUS. Sebastian Wiberg
• Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early after Surgical Bioprosthetic Valve Replacement: ENBALV trial. Presented by Chisato Izumi.
• CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction. The results of the spironolactone factorial. Presented by Sanjit S. Jolly.
Innovation in Prevention and Global Implementation
Sunday, Nov. 17, 3:30 - 4:45 p.m., Main Event I
• TOPSPIN: A Three-arm Randomized Trial For Treatment Optimisation Of Blood Pressure With Single-pill Combinations In India. Presented by Dimple Kondal, Dorairaj Prabhakaran.
• Electronic Nudges to Increase Influenza Vaccination among Patients with History of Myocardial Infarction: Insights from 3 Randomized Clinical Trials Enrolling >2 Million Patients: NUDGE-FLU. Presented by Ankeet Bhatt.
• Pragmatic Randomized Controlled Trial of a Decision Support System to Aid Physician Optimization of Early Lipid Lowering Therapies after Acute Coronary Syndrome: ZODIAC. Presented by Kausik K. Ray.
• Preliminary Results of New Versus Reconditioned Pacemakers for Patients Unable to Obtain a New Device in Low- and Middle-Income Countries: The My Heart Your Heart (MHYH) Randomized Controlled Trial. Presented by Thomas Crawford.
Featured Science: Vascular Outcomes in the Spotlight
Monday, Nov. 18. 8 - 9:15 a.m., S100A
• Evolution of Novel Therapies in Vascular Medicine. Presented by Joshua A. Beckman.
• Geographical variations of treatment disparities between Black and white patients with peripheral artery disease across the United States. Presented by Birgit Vogel.
• Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double Blind, Randomized, Placebo Controlled Study. Presented by David G. Armstrong, Michael S. Conte.
• Bempedoic Acid and Limb Outcomes in Statin-Intolerant Patients with Peripheral Artery Disease: New insights from the CLEAR OUTCOMES trial. Presented by Marc P. Bonaca.
• Rivaroxaban for 18 Months versus 6 Months in Cancer Patients with Low-risk Pulmonary Embolism: ONCO PE Trial. Presented by Yugo Yamashita.
Building on the 4 Pillars: Novel Trials of Medical Therapy for Heart Failure
Monday, Nov. 18, 8 - 9:15 a.m., Main Event I
• Myeloperoxidase Inhibition with Mitiperstat in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Primary Results from the ENDEAVOR Randomized Clinical Trial. Presented by Sanjiv J. Shah.
• Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial – The SARAH Trial. Presented by Marcely Gimenes Bonatto.
• Novel Bumetanide Nasal Spray (BNS) Demonstrates Safety, Tolerability, and Equivalent Efficacy Compared to Intravenous and Oral Bumetanide.
Presented by Daniel R. Bensimhon.
• Sodium Zirconium Cyclosilicate and MRA Optimization in Heart Failure With Reduced Ejection Fraction and Hyperkalemia: Main Results From REALIZE-K Randomized Controlled Trial. Presented by Mikhail N Kosiborod.
• Summary: The Future of Medical Therapy for Heart Failure. Presented by Douglas L. Mann.
Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations
Monday, Nov. 18, 9:45 - 11 a.m., S103BC
• Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy with Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy. Presented by Joseph Rossano.
• Mavacamten Treatment in Patients with Obstructive HCM Referred for Septal Reduction Therapy: 128-Week Results from VALOR-HCM Trial. Presented by Milind Y. Desai.
• Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study. Presented by Daniel P. Judge.
• Impact of vutrisiran on outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial. Presented by Marianna Fontana.
• The prevalence of transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure: The Screening for Cardiac Amyloidosis with Nuclear imaging in Minority Populations Study: SCAN-MP. Presented by Frederick Ruberg.
• ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis. Presented by Christian Nitsche.
Revolutionizing AF Management: Cutting-Edge Approaches
Monday, Nov. 18, 9:45 - 11 a.m., Main Event I
• Comparison of Linear Ablation Plus Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone for Persistent Atrial Fibrillation: Results from the PROMPT-AF Randomized Trial. Presented by Caihua Sang.
• Cryoballoon Ablation versus Radiofrequency Ablation in Patients with Persistent Atrial Fibrillation (CRRF-PeAF): A Prospective, Multicenter, Randomized, Non-inferiority Clinical Trial. Presented by Kengo F. Kusano.
• Randomized Controlled Trial of Metformin and Lifestyle/Risk Factor Modification for Upstream Prevention of Atrial Fibrillation Progression: The Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF) Trial. Presented by Mina K. Chung.
• Aggressive Risk factor REduction STudy for Atrial Fibrillation (ARREST-AF) implications for ablation outcomes: A Randomized Clinical Trial. Presented by Rajeev K. Pathak.
Featured Science: Novel Insights in Cardiovascular Interventional Outcomes
Monday, Nov. 18, 1:30 - 2:45 p.m., S100A
• Semaglutide Improves Cardiovascular Outcomes in Patients with a History of Coronary Artery Bypass Surgery and Overweight or Obesity: The SELECT Trial. Presented by Subodh Verma.
• Five-Year Results from the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE). Presented by Dhanunjaya Lakkireddy.
• The impact of carbon monoxide to determine the in-hospital prognosis of myocardial infarction: ADDICT-ICCU. Presented by Manveer Singh.
• Quantitative Assessment of Mitral Annular Calcification Severity Predicts Outcomes in Severe Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Replacement. Presented by Chieh-Mei Tsai.
Featured Science: Incretin Modulation: Is a New Standard of Care Emerging?
Monday, Nov. 18, 1:30 - 2:45 p.m., S103BC
• Effect of Tirzepatide on Cardiac Structure and Function in Obese HFpEF: the SUMMIT CMR Substudy. Presented by Christopher M. Kramer.
• Effects of Tirzepatide on the Clinical and Symptom Burden of Patients with Heart Failure and a Preserved Ejection Fraction, Results from the SUMMIT Trial. Presented by Michael R. Zile.
• Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial. Presented by Katherine R. Tuttle.
• Incretin Analogues for Addressing Multisystem Morbidity.
New Targets and New Treatments: Advances in Lipid Therapeutics
Monday, Nov. 18, 1:30 - 2:45 p.m., Main Event I
• History and future of lipid therapeutics- a time of Renaissance. Presented by Pamela B Morris.
• ALPACAR Phase 2 Trial of Zerlasiran: Multiple doses of a Small-Interfering RNA Targeting Lipoprotein(a) with 60 weeks Folow Up. Presented by Steven E. Nissen.
• A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles. Presented by Stephen Nicholls.
• Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia. Presented by Stephen Nicholls.
Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: dfornell@innovatehealthcare.com